These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
293 related articles for article (PubMed ID: 19878335)
21. Prophylactic bypassing agent use before and during immune tolerance induction in patients with haemophilia A and inhibitors to FVIII. Carpenter SL; Khair K; Gringeri A; Valentino LA Haemophilia; 2018 Jul; 24(4):570-577. PubMed ID: 29901839 [TBL] [Abstract][Full Text] [Related]
22. Inhibitors in haemophilia A: current management and open issues. Haya S; Moret A; Cid AR; Cortina V; Casaña P; Cabrera N; Aznar JA Haemophilia; 2007 Dec; 13 Suppl 5():52-60. PubMed ID: 18078398 [TBL] [Abstract][Full Text] [Related]
23. Therapeutic management and costs of severe haemophilia A patients with inhibitors in Italy. Abbonizio F; Giampaolo A; Coppola A; ; Arcieri R; Hassan HJ Haemophilia; 2014 Jul; 20(4):e243-50. PubMed ID: 24834967 [TBL] [Abstract][Full Text] [Related]
24. Successful immune tolerance induction with low-dose coagulation factor VIII in a patient with hemophilia A from a developing country. Ay Y; Ersin T; Yesim O; Hilkay KT; Dilek I; Gulcihan O; Ahmet K Blood Coagul Fibrinolysis; 2016 Sep; 27(6):729-31. PubMed ID: 26484639 [TBL] [Abstract][Full Text] [Related]
25. Optimizing factor prophylaxis for the haemophilia population: where do we stand? Blanchette VS; Manco-Johnson M; Santagostino E; Ljung R Haemophilia; 2004 Oct; 10 Suppl 4():97-104. PubMed ID: 15479380 [TBL] [Abstract][Full Text] [Related]
26. A retrospective postlicensure survey of FEIBA efficacy and safety. Dimichele D; Négrier C Haemophilia; 2006 Jul; 12(4):352-62. PubMed ID: 16834734 [TBL] [Abstract][Full Text] [Related]
27. How I treat inhibitors in haemophilia. Makris M; Hay CR; Gringeri A; D'Oiron R Haemophilia; 2012 Jul; 18 Suppl 4():48-53. PubMed ID: 22726083 [TBL] [Abstract][Full Text] [Related]
28. Discontinuing early prophylaxis in severe haemophilia leads to deterioration of joint status despite low bleeding rates. Nijdam A; Foppen W; De Kleijn P; Mauser-Bunschoten EP; Roosendaal G; van Galen KP; Schutgens RE; van der Schouw YT; Fischer K Thromb Haemost; 2016 May; 115(5):931-8. PubMed ID: 26791021 [TBL] [Abstract][Full Text] [Related]
29. Some recent developments regarding arthropathy and inhibitors in haemophilia. Rodriguez-Merchan EC Haemophilia; 2008 Mar; 14(2):242-7. PubMed ID: 18201189 [TBL] [Abstract][Full Text] [Related]
30. Estimating the potential cost of a high dose immune tolerance induction (ITI) therapy relative to the cost of a combined therapy of a low dose ITI therapy with bypassing agent prophylaxis. Kenet G; Oladapo A; Epstein JD; Thompson C; Novack A; Nugent DJ Haemophilia; 2017 Sep; 23(5):e394-e402. PubMed ID: 28641362 [TBL] [Abstract][Full Text] [Related]
32. Combined treatment with APCC (FEIBA®) and tranexamic acid in patients with haemophilia A with inhibitors and in patients with acquired haemophilia A--a two-centre experience. Holmström M; Tran HT; Holme PA Haemophilia; 2012 Jul; 18(4):544-9. PubMed ID: 22348384 [TBL] [Abstract][Full Text] [Related]
33. Immune tolerance induction in haemophilia A patients with inhibitors by treatment with recombinant factor VIII: a retrospective non-interventional study. Rivard GE; Rothschild C; Toll T; Achilles K Haemophilia; 2013 May; 19(3):449-55. PubMed ID: 23510123 [TBL] [Abstract][Full Text] [Related]
34. Successful low dose immune tolerance induction in severe haemophilia A with inhibitors below 40 Bethesda Units. Ter Avest PC; Fischer K; Gouw SC; Van Dijk K; Mauser-Bunschoten EP Haemophilia; 2010 May; 16(102):71-9. PubMed ID: 20536988 [TBL] [Abstract][Full Text] [Related]
35. Importance of rapid bleeding control in haemophilia complicated by inhibitors. Berntorp E Haemophilia; 2011 Jan; 17(1):11-6. PubMed ID: 20565546 [TBL] [Abstract][Full Text] [Related]
36. Anti-inhibitor coagulant complex prophylaxis in hemophilia with inhibitors. Leissinger C; Gringeri A; Antmen B; Berntorp E; Biasoli C; Carpenter S; Cortesi P; Jo H; Kavakli K; Lassila R; Morfini M; Négrier C; Rocino A; Schramm W; Serban M; Uscatescu MV; Windyga J; Zülfikar B; Mantovani L N Engl J Med; 2011 Nov; 365(18):1684-92. PubMed ID: 22047559 [TBL] [Abstract][Full Text] [Related]
37. Immune tolerance induction with a high purity von Willebrand factor/VIII complex concentrate in haemophilia A patients with inhibitors at high risk of a poor response. Gringeri A; Musso R; Mazzucconi MG; Piseddu G; Schiavoni M; Pignoloni P; Mannucci PM; Haemophilia; 2007 Jul; 13(4):373-9. PubMed ID: 17610550 [TBL] [Abstract][Full Text] [Related]
38. A decade-long clinical experience on the prophylactic use of activated prothrombin complex concentrate in acquired haemophilia A: a case series from a tertiary care centre. Árokszállási A; Rázsó K; Ilonczai P; Oláh Z; Bereczky Z; Boda Z; Schlammadinger Á Blood Coagul Fibrinolysis; 2018 Apr; 29(3):282-287. PubMed ID: 29474202 [TBL] [Abstract][Full Text] [Related]
39. Haemophilia care in children--benefits of early prophylaxis for inhibitor prevention. Mancuso ME; Graca L; Auerswald G; Santagostino E Haemophilia; 2009 Jan; 15 Suppl 1():8-14. PubMed ID: 19125935 [TBL] [Abstract][Full Text] [Related]
40. Forum on: the role of recombinant factor VIII in children with severe haemophilia A. Franchini M; Coppola A; Molinari AC; Santoro C; Schinco P; Speciale V; Tagliaferri A Haemophilia; 2009 Mar; 15(2):578-86. PubMed ID: 19187188 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]